Adicet Bio Inc (ACET) Stock Price, Quote & News

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmun...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 503 9095

Website: www.adicetbio.com

Address:

131 Dartmouth Street, 3rd Floor, Boston, United States

Gator5326 Dec. 4 at 8:19 PM

$ACET Long term? LMAO. CEO does a raise same day of news. Only one sucker bought into that raise. Then he announces a between 1-5 to 1-30 RS to be voted on the 19th of this month! What a freakin scam before your eyes and you still try to pump?

0 · Reply

Zgod Dec. 4 at 3:56 PM

$ACET just because the rs vote is 12/19 does not mean they will use it right away. They have until April for compliance

1 · Reply

BioTechChap Dec. 3 at 7:49 PM

$ACET What a gift. Will buy even more upon RS. 2026 looks very bright.

0 · Reply

mikedumbledar Dec. 3 at 7:39 PM

$ACET nobody takes this company seriously. the only thing they have going is the tribe funds their own. that is how they do these offerings at $1 and such. straight down after that offering looks like all-time lows coming in the next week or so

1 · Reply

Gator5326 Dec. 3 at 3:33 PM

$ACET Timber!!!! Thank the CEO, if you can call him that.

0 · Reply

Hereinbama35 Dec. 3 at 2:51 PM

$ACET A Zack’s rating of 2? 7 analyst buy ratings and a media price forecast of 1,300%? Sure, I’ll take a small shot here.

2 · Reply

Gator5326 Dec. 2 at 5:05 PM

$ACET Anything bought now is a loss. You are being scammed by the powers that be. Up to 1-30 RS being voted on in 17 days. What a scam

0 · Reply

Khamas Dec. 2 at 4:45 PM

$ACET crafty MM buggers .... sucked in more buyers in late 60s before they pull it below .50

0 · Reply

Zgod Dec. 2 at 4:41 PM

$ACET not selling a share until trial results!

0 · Reply

Iightning Dec. 2 at 2:51 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $ACET **Contract:** Dec 19 $7.5C **Entry:** 0.28 **Exit:** 0.37 **Return:** **+34.59% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Nov 5, 2025, 4:01 PM EST - 4 weeks ago

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 31, 2025, 4:59 PM EDT - 4 weeks ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 28, 2025, 7:00 AM EDT - 5 weeks ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

$Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)$

Oct 16, 2025, 7:00 AM EDT - 7 weeks ago

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Oct 7, 2025, 12:35 PM EDT - 2 months ago

Adicet Bio, Inc. - Special Call

Oct 7, 2025, 11:05 AM EDT - 2 months ago

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Oct 7, 2025, 7:01 AM EDT - 2 months ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Oct 7, 2025, 6:45 AM EDT - 2 months ago

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Sep 2, 2025, 7:00 AM EDT - 3 months ago

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:14 PM EDT - 4 months ago

Adicet Bio (ACET) Q2 Loss Widens 3%

Aug 7, 2025, 4:01 PM EDT - 4 months ago

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 5, 2025, 7:00 AM EDT - 4 months ago

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Jul 24, 2025, 7:00 AM EDT - 4 months ago

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

May 21, 2025, 4:00 PM EDT - 7 months ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 6, 2025, 4:01 PM EDT - 7 months ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 30, 2025, 7:00 AM EDT - 7 months ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 28, 2025, 4:30 PM EDT - 7 months ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 8 months ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Mar 31, 2025, 5:12 PM EDT - 8 months ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 6, 2025, 4:01 PM EST - 9 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 3, 2025, 7:00 AM EST - 9 months ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Feb 27, 2025, 7:00 AM EST - 10 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

$Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement$

Feb 5, 2025, 7:10 AM EST - 10 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Jan 29, 2025, 7:00 AM EST - 11 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 8, 2025, 4:10 PM EST - 11 months ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Dec 19, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Nov 18, 2024, 4:00 PM EST - 1 year ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 16, 2024, 9:00 AM EST - 1 year ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 5, 2024, 7:00 AM EST - 1 year ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Sep 30, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Aug 27, 2024, 4:00 PM EDT - 1 year ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

May 29, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

May 14, 2024, 4:01 PM EDT - 1 year ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

May 14, 2024, 10:00 AM EDT - 1 year ago

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Gator5326 Dec. 4 at 8:19 PM

0 · Reply

Zgod Dec. 4 at 3:56 PM

$ACET just because the rs vote is 12/19 does not mean they will use it right away. They have until April for compliance

1 · Reply

BioTechChap Dec. 3 at 7:49 PM

$ACET What a gift. Will buy even more upon RS. 2026 looks very bright.

0 · Reply

mikedumbledar Dec. 3 at 7:39 PM

1 · Reply

Gator5326 Dec. 3 at 3:33 PM

$ACET Timber!!!! Thank the CEO, if you can call him that.

0 · Reply

Hereinbama35 Dec. 3 at 2:51 PM

$ACET A Zack’s rating of 2? 7 analyst buy ratings and a media price forecast of 1,300%? Sure, I’ll take a small shot here.

2 · Reply

Gator5326 Dec. 2 at 5:05 PM

$ACET Anything bought now is a loss. You are being scammed by the powers that be. Up to 1-30 RS being voted on in 17 days. What a scam

0 · Reply

Khamas Dec. 2 at 4:45 PM

$ACET crafty MM buggers .... sucked in more buyers in late 60s before they pull it below .50

0 · Reply

Zgod Dec. 2 at 4:41 PM

$ACET not selling a share until trial results!

0 · Reply

Iightning Dec. 2 at 2:51 AM

0 · Reply

Shane_Drinion Nov. 28 at 3:29 PM

$ACET Why?

1 · Reply

Zgod Nov. 28 at 3:18 PM

$ACET fly baby, fly!

0 · Reply

d00bie Nov. 28 at 1:54 PM

$ACET ..

0 · Reply

Gator5326 Nov. 28 at 1:39 PM

$ACET Buying into a train wreck. This CEO purposely destroying this company. Nobody is that stupid do do what he has done. 🤦‍♂️

0 · Reply

MiltonMilkyMilkovich Nov. 26 at 8:50 PM

$ACET someone casually dumps 2.5 million shares into the bid. haha everybody wants out, even at huge at a huge loss. none of the Tang, RA capital , orbimed have ever been green here. always underwater, eh boys? ha

1 · Reply

Zgod Nov. 26 at 7:10 PM

$ACET RS vote isn’t until dec 19 and even if approved, they have extension until april and may not need it if the price naturally recovers. Let’s get it there!

1 · Reply

sixmilliondollarman Nov. 26 at 3:01 PM

$ACET there’s no way to know and a lot of time for anything to happen. Three recent examples where I’ve had positions. MRSN traded down after RS then acquired 3 months later for 3X pre split price. GBIO traded almost 2X higher post RS and is still higher. STRO voted for RS but didn’t implement right away and has since regained compliance, no RS. RS votes for ACET next month but still has until April for compliance. Anything can happen! 🤷‍♂️

3 · Reply

Iightning Nov. 26 at 5:53 AM

1ightning® Options Trade Alert (Actionable) | Buy $ACET Dec 19 $1 Call | Enter: $0.05 Exit: $0.07 | Profit: 36.05% ROI | https://1ightning.com

1 · Reply

Iightning Nov. 25 at 4:01 PM

1ightning® Options Trade Alert (Actionable) | Buy $ACET Dec 19 $1 Call | Enter: $0.05 Exit: $0.07 | Profit: 36.05% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:55 AM

1ightning® Options Trade Alert (Actionable) | Buy $ACET Dec 19 $1 Call | Enter: $0.05 Exit: $0.07 | Profit: 36.05% ROI | https://1ightning.com

0 · Reply

MoonShine007 Nov. 24 at 3:55 PM

$ACET No retailers in this one anymore? 🔥

4 · Reply

Iightning Nov. 22 at 2:06 AM

1ightning® Options Trade Alert (Actionable) | Buy $ACET Dec 19 $2 Call | Enter: $0.36 Exit: $0.46 | Profit: 27.59% ROI | https://1ightning.com

0 · Reply

Market Cap	85.84M
Revenue (ttm)	0.00
Net Income (ttm)	-117.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,808,800
Avg Vol	2,278,934
Day's Range	N/A - N/A
Shares Out	153.26M
Stochastic %K	7%
Beta	1.61
Analysts	Strong Sell
Price Target	$7.17